Solid Biosciences announced today that they are working with the FDA to resolve questions related the to clinical hold placed on the IGNITE DMD trial in Duchenne muscular dystrophy patients. The trial was placed on full clinical hold after the first patient dosed with SGT-001 experienced a serious adverse event. The company reported that the treating physician of the reported that the patient is doing well.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,